Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacopeia, Inc. (ACCL) (Prev: PCOP) -- Ignore unavailable to you. Want to Upgrade?

To: John Dwyer who wrote (78)	5/6/1998 1:26:00 PM
From: Jim Lang	Read Replies (1) \| Respond to of 179

John and others, A bit more news, this time about expanded analyst coverage from Legg-Mason. Again, no real 'beef' as others have said, but news nonetheless. Regarding the earlier news of reaching another milestone, it is true that not much was said, but the fact that they have successfully reached a point in a collaborative program sufficient to trigger cash payments gives me some comfort. It indicates to me that they continue to advance their R&D programs at an acceptible pace, as far as I can tell, and I am happy to hold on. But I would still like to see that $31 target reached that is mentioned in the following release!! PCOP continues to be underfollowed and underappreciated, as evidenced by the chronically low trading volume. Susan (or anyone else with access), perhaps you could publish the report mentioned below on the thread when you get a copy, or if it is too lengthy excerpts relevant to PCOP. Good trading, Jim Lang Wednesday May 6, 11:58 am Eastern Time Company Press Release SOURCE: Legg Mason Wood Walker, Inc. Legg Mason Initiates Research Coverage Of The Innovator Pharmaceuticals Industry BALTIMORE, May 6 /PRNewswire/ -- Legg Mason Wood Walker, Inc. announced today that it has initiated research coverage of the innovator pharmaceuticals industry and will issue an in-depth report on the industry by Stefan D. Loren, Ph.D. This report addresses key issues and trends in the industry as well as our investment perspective. Legg Mason Wood Walker, Inc. will also announce new research coverage of two companies within this sector. Pharmacopeia, Inc. (Nasdaq: PCOP - news; PCOP - $20-3/8)(a) Pharmacopeia, located in Princeton, New Jersey, is a leader in the field of combinatorial chemistry and its applications to drug discovery. An investment rating of Buy and a risk rating of Speculative have been assigned to Pharmacopeia along with a 12-18 month target price of $31. Agouron Pharmaceuticals Inc. (Nasdaq: AGPH - news; AGPH - $36-7/8)(a) San Diego, California-based Agouron specializes in the development of small-molecule anti-cancer and anti-viral therapeutics. AGPH was given an investment rating of Outperform with a risk rating of Speculative and a 12-18 month target price of $47. Legg Mason Wood Walker, Inc. is the principal securities brokerage subsidiary of Legg Mason, Inc. (NYSE: LM - news), with approximately 1,100 Financial Advisors in 110 offices along the East Coast from Maine to Florida and across the South to Texas, plus affiliate institutional offices in London, Paris, and Geneva. Legg Mason, Inc. is a financial services holding company that provides securities brokerage, discretionary asset management, investment banking, and commercial mortgage banking and related financial services through its wholly owned subsidiaries. (a) Prices are as of close on May 5, 1998. Legg Mason makes a market in the shares of Pharmacopeia, Inc. and Agouron Pharmaceuticals Inc. SOURCE: Legg Mason Wood Walker, Inc.